The city of Boston, Massachusetts, currently has 482 active clinical trials seeking participants for Cancer research studies.
SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)
Recruiting
SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Gastrointestinal Cancer, Thoracic Cancer, Hematologic Cancer
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Recruiting
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab to subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Exelixis Clinical Site #25, Boston, Massachusetts
Conditions: Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruiting
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Low Grade Fallopian Tube Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Ovarian Low Grade Serous Adenocarcinoma
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
Recruiting
This research study is studying a new drug, uproleselan, to see if it is safe and effective in decreasing relapse after stem cell transplant and improving leukemia-free survival in pediatric patients with acute myeloid leukemia (AML). The name of the study drugs involved in this study are: Uproleselan Busulfan Clofarabine Fludarabine Tacrolimus Methotrexate Mycophenolate Mofetil
Gender:
All
Ages:
Between 12 months and 39 years
Trial Updated:
04/30/2024
Locations: Boston Children's Hospital, Boston, Massachusetts +1 locations
Conditions: Acute Myeloid Leukemia, Pediatric Cancer
PRO1184 for Advanced Solid Tumors
Recruiting
This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Mesothelioma, Triple Negative Breast Cancer, High Grade Epithelial Ovarian Cancer, Breast Adenocarcinoma, Hormone Receptor-positive/Her2 Negative Breast Cancer
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Recruiting
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma, cholangiocarcinoma, gastric, pancreatic and colorectal cancer. The [18F]FAPI-74 PET scan will be acquired in patients with proven GI cancers after initial staging using institutional standard methods. The PET scan results will be compared to FAP immunohistochemistry (as the p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Massachusetts general hospital, Boston, Massachusetts
Conditions: Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Hepatocellular Carcinoma
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Recruiting
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Massachusetts General Hospital (Data Collection Only), Boston, Massachusetts
Conditions: Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
Recruiting
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Relapsed Small Cell Lung Cancer
Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors
Recruiting
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
04/30/2024
Locations: Research Site, Boston, Massachusetts
Conditions: Ovarian Cancer, Lung Adenocarcinoma
ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension
Recruiting
This research study is studying a drug intervention as a possible chemoprevention strategy for colorectal cancer. The name of the study intervention involved in this study is: Low Dose Aspirin
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Colorectal Cancer
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Recruiting
A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Castration Resistant Prostate Cancer (CRPC)
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Recruiting
The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the tumor. The Phase II portion of the trial has not started recruiting.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Rectal Cancer